Summary The National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium
(CPTAC) investigates tumors from a proteogenomic perspective, creating rich multi-omics …

The world has witnessed a steady rise in both non-infectious and infectious chronic
diseases, prompting a cross-disciplinary approach to understand and treating disease …

Genomic analyses in cancer have been enormously impactful, leading to the identification of
driver mutations and development of targeted therapies. But the functions of the vast majority …

Proteomics has become an important field in molecular sciences, as it provides valuable
information on the identity, expression levels, and modification of proteins. For example …

We performed the first proteogenomic characterization of hepatitis B virus (HBV)-related
hepatocellular carcinoma (HCC) using paired tumor and adjacent liver tissues from 159 …

High‐throughput methods to profile the genome, transcriptome, proteome and metabolome
of various systems has become a routine in multiple research laboratories around the world …

When it comes to precision oncology, proteogenomics may provide better prospects to the
clinical characterization of tumors, help make a more accurate diagnosis of cancer, and …

Data-independent acquisition mass spectrometry (DIA-MS) is a next generation proteomic
methodology that generates permanent digital proteome maps offering highly reproducible …

The integration of mass spectrometry-based proteomics with next-generation DNA and RNA
sequencing profiles tumors more comprehensively. Here this" proteogenomics" approach …

Fewer than 200 proteins are targeted by cancer drugs approved by the Food and Drug
Administration (FDA). We integrate Clinical Proteomic Tumor Analysis Consortium (CPTAC) …